Medication Description: Hydroxyurea (Hydroxyurea)
Oxy derivative of urea (see).
Synonyms: Hydrea, Hydroxycarbamide, Hydrea, Biosupressin, Hidrix, Hydroxycarbamide, Hydroxycarbamidum, Hydura, Litaliz, Onco-carbamidi.
As a chemical compound, hydroxyurea was synthesized in 1869, and only in 1982 its clinical effectiveness was proved in the treatment of certain forms of cancer.
Apply hydroxyurea for the treatment of chronic myeloid leukemia, Hodgkin's disease, melanoma, with metastasis of breast cancer.
The mechanism of antitumor activity is associated with the ability of a compound to inhibit ribonucleoside diphosphate reductase, which is one of the key enzymes involved in DNA biosynthesis.
The drug is easily absorbed by ingestion, the peak concentration in the blood plasma is observed after 1 to 2 hours, the half-life period is about 2 hours. It passes through the blood-brain barrier. About 80% is excreted in the urine within 12 hours.
Is taken orally in capsules containing 0.5 g of hydroxyurea. Usually prescribed 1 capsule 3-4 times a day. The course of treatment for 3 - 4 weeks. There are also other treatment regimens (80 mg / kg 1 every 3 days; 20 - 30 mg / kg daily; the duration of the treatment course is 6 weeks).
The drug is usually well tolerated. Perhaps the development of dyspeptic symptoms, skin allergic reactions, rarely stomatitis, as well as leukopenia, megaloplasticheskoy anemia, thrombocytopenia.
Side effects usually pass quickly after drug withdrawal.
Hydroxyurea is contraindicated in severe impairments of bone marrow function, severe anemia, and severe leukopenia during breastfeeding,
Form release: in capsules of 0.5 g in a package of 100 pieces.